多发性骨髓瘤靶向药物治疗进展：第56届美国血液学会年会报道

Progress of targeted therapy in multiple myeloma： reports from the 56th American Society of Hematology annual meeting

随着对多发性骨髓瘤（MM）分子发病机制研究的深入，许多新的靶向治疗药物进入临床试验，使MM患者的缓解率和生存质量得到进一步提高。2014年第56届美国血液学会（ASH）年会针对MM的靶向治疗最新进展进行了专题报道，这些药物临床试验结果均明显提高了MM的疗效，或许将给MM的治疗策略带来重大改变。现将会议上报道的针对MM的分子靶向治疗药物研究新进展进行介绍。

With the further study on molecular pathogenesis of muhiple myeloma （MM）, lots of novel targeted therapies emerged into clinical trials, which improved the response rate and life quality of MM patients. In the 56th American Society of Hematology （ASH） annual meeting, a series of special reports about latest developments in targeted therapy for MM patients were published. Efficacy was improved significantly by these reagents, which may provide the new treatment strategies for MM patients. The advances in the novel targeted therapies will be summarized in this paper based on the new reports in the 56th ASH annual meeting.